Harvard Bioscience, Inc. (NASDAQ:HBIO) Sees Large Growth in Short Interest

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 350,600 shares, a growth of 11.4% from the September 30th total of 314,700 shares. Based on an average daily volume of 110,600 shares, the short-interest ratio is currently 3.2 days.

Institutional Investors Weigh In On Harvard Bioscience

A number of large investors have recently modified their holdings of the business. Greenwood Capital Associates LLC lifted its stake in shares of Harvard Bioscience by 9.1% in the third quarter. Greenwood Capital Associates LLC now owns 225,866 shares of the medical instruments supplier’s stock worth $608,000 after buying an additional 18,932 shares in the last quarter. Brighton Jones LLC acquired a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $68,000. SG Americas Securities LLC acquired a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $36,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Harvard Bioscience in the second quarter valued at approximately $40,000. Finally, Meros Investment Management LP increased its holdings in shares of Harvard Bioscience by 1.6% in the second quarter. Meros Investment Management LP now owns 835,213 shares of the medical instruments supplier’s stock valued at $2,380,000 after purchasing an additional 13,421 shares during the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

Harvard Bioscience stock traded down $0.10 during midday trading on Thursday, reaching $2.35. The company had a trading volume of 62,683 shares, compared to its average volume of 113,688. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.05 and a quick ratio of 0.94. Harvard Bioscience has a 12-month low of $2.30 and a 12-month high of $5.56. The company has a market capitalization of $102.06 million, a P/E ratio of -11.90 and a beta of 1.29. The firm’s fifty day simple moving average is $2.65 and its 200-day simple moving average is $3.02.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.06). Harvard Bioscience had a negative net margin of 10.56% and a negative return on equity of 2.70%. The firm had revenue of $23.10 million during the quarter, compared to analysts’ expectations of $29.91 million. As a group, equities analysts anticipate that Harvard Bioscience will post 0.11 EPS for the current year.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.